Every material Form 8-K HeartSciences Inc. has filed with the SEC since September 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HeartSciences filed an 8-K with supplemental disclosures to its proxy statement for the proposed merger with Fortitude Mining Holdings, a subsidiary of Digital Currency Group. The company received seven demand letters from purported shareholders alleging the proxy omits material information, and says the claims are without merit but is voluntarily adding disclosures to avoid delays and litigation expense. The special meeting remains scheduled for November 19, 2026, so the disclosures do not change the vote timing.
Seven demand letters received from counsel to purported shareholders alleging proxy omissions.
Company denies the allegations and says disclosures are voluntary, made without admitting liability.
Supplemental disclosures include a January 6, 2026 letter of intent with Fortitude and an indicated equity value range for Fortitude of $206.0 million to $428.2 million.
Special Meeting to be held virtually on November 19, 2026, at 10:00 a.m. Eastern Time.
On October 6, 2026, HeartSciences said the FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph, but the clearance does not include the AI-ECG algorithm. The company does not intend to commercialize the device without a cleared algorithm and has no timeline for doing so, and it will evaluate options for the device and related intellectual property. The proposed business combination with Fortitude Mining Holdings continues, with closing expected in Q4 calendar 2026, subject to shareholder approval.
FDA granted 510(k) clearance K260005 for the MyoVista wavECG device as a 12-lead resting electrocardiograph, covering adult and pediatric patients in hospitals and healthcare facilities.
The clearance does not include the AI-ECG algorithm, and the company has no commercialization timeline for the device.
The Proposed Transaction with Fortitude, under a merger agreement dated June 23, 2026, is expected to close in Q4 calendar 2026, subject to shareholder approval.
HeartSciences entered Amendment No. 8 to its Loan and Security Agreement and a No. 4 Amended and Restated Secured Promissory Note with Front Range Ventures LLC, both dated September 29, 2026. The amendment extends the maturity of the note, which funded a $500,000 borrowing, to the earlier of two business days after closing of the proposed business combination with Fortitude Mining Holdings, Inc. or January 29, 2027. The filing states the change to the note's terms but does not report any change in the loan amount.
The note's maturity date is extended to the earlier of two business days after the Fortitude Mining Holdings, Inc. business combination closes or January 29, 2027.
Accrued unpaid interest as of September 30, 2026 is payable on or before that date; later accrued interest is payable at maturity.
The company may repay all or part of the principal at any time before maturity, in amounts of at least $50,000, applied first to interest.
Fortitude Mining Holdings, the business HeartSciences has agreed to combine with under a June 23, 2026 merger agreement, appointed Jaime Leverton as its Chief Executive Officer and a board member, effective September 21, 2026. Andrea Childs resigned from the Fortitude board and will step down as CEO on that date to become Chief Operating Officer. The filing says Leverton is expected to lead the combined company after the deal closes, which is expected in the fourth quarter of 2026 subject to HeartSciences shareholder approval.
Jaime Leverton becomes CEO and a director of Fortitude effective September 21, 2026; she previously served as CEO of Hut 8 and most recently led ReserveOne.
Andrea Childs resigns from the Fortitude board effective immediately and becomes Chief Operating Officer on September 21, 2026.
The merger agreement was signed June 23, 2026; closing is expected in the fourth quarter of 2026, subject to HeartSciences shareholder approval.
Fortitude reported second quarter revenue of $20.9 million, according to the press release furnished as Exhibit 99.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HeartSciences Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →